COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00755911
Recruitment Status : Completed
First Posted : September 19, 2008
Results First Posted : April 15, 2014
Last Update Posted : July 3, 2015
Vericel Corporation
Information provided by (Responsible Party):
Darnell Kaigler, University of Michigan

Brief Summary:
The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Cell (TRC) Therapy.

Condition or disease Intervention/treatment Phase
Alveolar Bone Loss Biological: Tissue Repair Cells (TRC) Device: Control Phase 1 Phase 2

Detailed Description:
A sample of the subject's bone marrow tissue will be collected and sent to a laboratory where it will be processed to form cells. The new cells are transplanted into the tooth socket after the tooth has been removed. The researchers are testing to see if these cells (TRC) will help form bone. The research will also determine if the implant the subject receives will be more stable in the area with new bone growth.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
Study Start Date : June 2008
Actual Primary Completion Date : December 2011
Actual Study Completion Date : May 2012

Arm Intervention/treatment
Experimental: Tissue Repair Cells (TRC)
Subjects will receive Tissue Repair Cell (TRC) therapy plus Gelfoam carrier
Biological: Tissue Repair Cells (TRC)
30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
Other Name: Tissue Repair Cells, Bone Repair Cells, ixmyelocel-t

Device: Control
Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
Other Name: Gelfoam

Sham Comparator: Control
Subjects will receive the control treatment, consisting of Gelfoam carrier without Tissue Repair Cell (TRC) therapy.
Device: Control
Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
Other Name: Gelfoam

Primary Outcome Measures :
  1. Bone Regeneration [ Time Frame: 12 months after tooth extraction ]

    The primary objective of this study is to determine whether the placement of Tissue Repair Cells (TRCs) at the time of tooth extraction can safely and effectively promote bone regeneration in alveolar bone defects created by tooth extraction.

    • Safety was assessed through adverse event reporting
    • Bone regeneration was assessed through measures of bone mineral density and bone volume fraction of biopsied regenerated bone tissue. Bone regeneration was also measured through radiographic analysis of relative bone height gain (% of the bone height regenerated relative to the height before tooth extraction)

Secondary Outcome Measures :
  1. Number of Participants Who Successfully Received Dental Implant Fixtures [ Time Frame: 12 months after tooth extraction ]
    The secondary objective is to determine if Tissue Repair Cell therapy regenerates bone enabling the installation and stability of dental implant fixtures

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age range: 20 to 70 years
  • Gender: Male and female
  • Patients must be able and willing to follow study procedures and instructions
  • Patients must have read, understood and signed an informed consent form
  • Patients must require tooth extraction as a result of caries, periodontal disease, or tooth fracture

Exclusion Criteria:

  • Allergies or hypersensitivities to study related medications: amoxicillin, dexamethasone, chlorhexidine, ibuprofen, ranitidine
  • Hematologic disorders/ blood dyscrasias
  • Active infectious disease
  • Liver or kidney dysfunction/failure- Patients will have blood drawn for serum laboratory tests, including creatinine, blood urea nitrogen (BUN), aspartate aminotransferase (AST), alanine aminotransferase test (ALT), and bilirubin. All of these must be within normal limits for a patient to be included in the study. Current University of Michigan Health System normal lab values are as follows: Creatinine (male 0.7-1.3 mg/dl; female 0.5-1.0 mg/dl); BUN (8-20 mg/dl); AST (8-30 IU/L); ALT (7-35 IU/L); Bilirubin (0.2-1.2 mg/dl).
  • Endocrine disorders/dysfunctions (i.e Type I and II diabetes)
  • Cancer - The explicit definition of cancer used to exclude patients is consistent with that described by the National Cancer Institute (NCI), National Institutes of Health. According to NCI, cancer is any disease in which abnormal cells divide without control and invade nearby tissues (invasive disease). These include carcinomas, sarcomas, leukemias, and lymphomas. Any patient with a history of these invasive diseases will be excluded from the study.
  • Patients who currently use bisphosphonates or have a history of bisphosphonate use will be excluded from the trial.
  • HIV+
  • Metabolic Bone Diseases-Patients with metabolic bone diseases such as Paget's disease, hypercalcemia, moderate to severe vitamin D3 abnormalities or any other metabolic bone disease including osteoporosis and osteoporotic fractures will be excluded. The following scale will be used to determine osteoporosis in patients who have had a bone mass density (BMD) determination: Normal = T score at or above -1.0 SD; Osteopenia = T score between -1.0 and -2.5 SD; Osteoporosis = T score at or below -2.5 standard deviation (SD). Although a dexa scan will not be required, all post-menopausal women receiving osteoporosis/osteopenia related therapy will receive a dexa scan as part of their standard medical care.
  • Additionally, individuals who have a medical history significant for diabetes will not be included in the study.
  • Laboratory values that will define normal renal and hepatic function, as well as criteria for exclusion of metabolic bone disease are consistent with those established by the University of Michigan Health System (UMHS). Normal clinical values will be used to help assure the health of all subjects in this trial.
  • Individuals who have a BMI outside normal limits or a BMI that deems them overweight (BMI >25) will be excluded due to potential difficulties in locating appropriate surgical entry of the iliac crest during bone marrow aspiration procedure.
  • The following additional exclusion criteria for regenerative sites are in alignment with those described and adapted for using bone morphogenetic protein (BMPs) to regenerate buccal wall defects (Fiorellini, Howell et al. 2005):
  • Patients < 20 and > 60 years of age
  • Pregnant women- Female patients who are of childbearing potential are excluded except those who are using hormonal or barrier methods of birth control (oral or parenteral contraceptives, transdermal patch, diaphragm plus spermicide, or condoms). Pregnancy status will be determined with a urine test and patients who are pregnant, as determined by a positive test, will be excluded from the study
  • Patients with acute sinusitis
  • Patients with congenital or metabolic bone disorders
  • Current smokers (have smoked within 6 mos. of study onset)
  • Presence of < 4 mm of bone from apex of tooth to the alveolar crest
  • < 2 mm bone from apex to floor of maxillary sinus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00755911

Layout table for location information
United States, Michigan
University of Michigan Center for Oral Health Research
Ann Arbor, Michigan, United States, 48106
Sponsors and Collaborators
University of Michigan
Vericel Corporation
Layout table for investigator information
Principal Investigator: Darnell Kaigler, DDS, MS, PhD University of Michigan Department of Periodontics and Oral Medicine
Study Chair: William V Giannobile, DDS, DMedSc University of Michigan Center for Oral Health Research
Study Chair: Steven Goldstein, PhD University of Michigan Henry Ruppenthal Family Professor of Orthopaedic Surgery and Bioengineering
Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Darnell Kaigler, Principal Investigator, University of Michigan Identifier: NCT00755911    
Other Study ID Numbers: 2008-02
First Posted: September 19, 2008    Key Record Dates
Results First Posted: April 15, 2014
Last Update Posted: July 3, 2015
Last Verified: May 2015
Keywords provided by Darnell Kaigler, University of Michigan:
Additional relevant MeSH terms:
Layout table for MeSH terms
Alveolar Bone Loss
Bone Resorption
Bone Diseases
Musculoskeletal Diseases
Periodontal Atrophy
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Gelatin Sponge, Absorbable